After Tacti-003’s controlled cohorts fail, Immutep plays up single-arm data in PD-L1 non-expressers.

But ficerafusp is limited to HPV-negative disease, and petosemtamab’s safety looks better.

One of the German group’s biggest cancer hopes has fallen flat, raising more questions about targeting an apoptosis pathway.

Early release of petosemtamab’s ASCO data suggest that analysts’ bull case has been met.

Petosemtamab meets sellside forecasts, but for the bull case you need to include an unconfirmed response.

ASCO is fast approaching, but in the meantime Olema will have an important readout.

A phase 2 head and neck trial missed its primary endpoint, but the group is taking heart from survival data.

Hopes are high for petosemtamab head and neck data at ASCO, but what does a win look like?